173 related articles for article (PubMed ID: 38341200)
21. Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Kumar A; Fraz MA; Usman M; Malik SU; Ijaz A; Durer C; Durer S; Tariq MJ; Khan AY; Qureshi A; Faridi W; Nasar A; Anwer F
Curr Treat Options Oncol; 2018 Sep; 19(10):50. PubMed ID: 30173370
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge.
Lavacchi D; Landini I; Perrone G; Roviello G; Mini E; Nobili S
Pharmacol Ther; 2022 Jan; 229():107924. PubMed ID: 34175369
[TBL] [Abstract][Full Text] [Related]
23. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
[TBL] [Abstract][Full Text] [Related]
24. A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).
Chung MJ; Cho WK; Oh D; Eom KY; Kim JH; Kim WC; Lee JH
J Radiat Res; 2019 Oct; 60(5):677-684. PubMed ID: 31251343
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
26. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.
Herbrecht R; Cernohous P; Engert A; Le Gouill S; Macdonald D; Machida C; Myint H; Saleh A; Singer J; Wilhelm M; van der Jagt R
Ann Oncol; 2013 Oct; 24(10):2618-2623. PubMed ID: 23946328
[TBL] [Abstract][Full Text] [Related]
27. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
He HX; Gao Y; Bai B; Wang XX; Li JB; Huang C; Mao JY; Ping LQ; Rong QX; He YX; Huang H; Cai QQ; Li ZM; Jiang WQ; Huang HQ
Cancer Med; 2021 Nov; 10(21):7650-7664. PubMed ID: 34581023
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
29. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?
Major A; Smith SM
Clin Adv Hematol Oncol; 2021 Nov; 19(11):698-709. PubMed ID: 34807015
[TBL] [Abstract][Full Text] [Related]
30. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.
Sancho JM; Fernández-Alvarez R; Gual-Capllonch F; González-García E; Grande C; Gutiérrez N; Peñarrubia MJ; Batlle-López A; González-Barca E; Guinea JM; Gimeno E; Peñalver FJ; Fuertes M; Bastos M; Hernández-Rivas JÁ; Moraleda JM; García O; Sorigué M; Martin A
Cancer Med; 2021 Feb; 10(4):1314-1326. PubMed ID: 33492774
[TBL] [Abstract][Full Text] [Related]
31. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
32. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
[TBL] [Abstract][Full Text] [Related]
33. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
Painschab MS; Kohler R; Kimani S; Mhango W; Kaimila B; Zuze T; Mithi V; Kasonkanji E; Mumba N; Nyasosela R; Wheeler S; Gopal S
Lancet Glob Health; 2021 Sep; 9(9):e1305-e1313. PubMed ID: 34303416
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
35. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China.
Sun JJ; Liu L; Wang JR; Shen YZ; Qi TK; Wang ZY; Tang Y; Song W; Chen J; Zhang RF
Chin Med J (Engl); 2020 Dec; 133(23):2796-2802. PubMed ID: 33273327
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
[TBL] [Abstract][Full Text] [Related]
38. Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
Ting CY; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
Int J Clin Pract; 2020 Oct; 74(10):e13594. PubMed ID: 32583545
[TBL] [Abstract][Full Text] [Related]
39. Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP.
Lee JY; Kang M; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Song KH; Kim ES; Kim HB; Lee KW; Kim JH; Bang SM; Lee JS; Lee JO
Mycoses; 2021 Jan; 64(1):60-65. PubMed ID: 32970331
[TBL] [Abstract][Full Text] [Related]
40. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
